 Patent Application Title |
Patent App Num. |
Date |
| Modification of factor viii | 20110306551 | 20111215 |
| A Factor VIII derivative of formula (I): wherein: B represents C2 to C10 alkylene; m represents 0 or an integer from 1 to 19, n represents an integer from 1 to 20, and the sum of m and n is from 1 to 20; P represents a mono or polyradical of Factor VIII obtained by removing m+n carbamoyl groups from the side chains of glutamine residues in Factor VIII; and M represents a moiety (M1) that increases the plasma half-life of the Factor VIII derivative or a reporter moiety (M2); or a pharmaceutically acceptable salt thereof.
... |
| Compositions and methods for treating or preventing conditions and diseases associated with mannheimia haemolytica | 20110296545 | 20111201 |
| Particular aspects show that the signal peptide remains intact on the mature CD18 molecule on ruminant leukocytes rendering these cells susceptible to cytolysis by Lkt. Comparative amino acid sequence analysis of the signal peptide of CD18 of eight ruminants and five non-ruminants revealed that the ruminant CD18 signal peptides contain ‘cleavage-inhibiting’ glutamine (Q), compared to ‘cleavage-conducive’ glycine in non-ruminants, at position −5 relative to the cleavage site. Mutagenesis of Q at position −5 of the bovine CD18 signal peptide to G resulted in the abrogation of Lkt-mediated cytolysis of transfectants expressing bovine CD18 carrying the Q(−5)G mutation. Provided is novel technology to clone cattle and other ruminants expressing CD18 without the signal peptide on their leukocytes, providing ruminants that are less susceptible to M. haemolytica. Methods... |
| Composition and method for treatment of diabetes | 20110275716 | 20111110 |
| The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract.
... |
| Conjugates for cancer therapy and diagnosis | 20110275590 | 20111110 |
| The present invention relates to conjugates of a drug and an amino acid or an amino acid derivative or analog, pharmaceutical compositions that include the conjugates and methods of use thereof. In particular, the present invention relates to conjugates of anti-proliferative drugs and asparagine and glutamine and analogs thereof as compositions for treatment of cancer, and conjugates of imaging agent carriers and amino acids for the diagnosis of tumors and metastases.
... |
| Novel inhibitors | 20110262388 | 20111027 |
| Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
... |
Subscribe to updates on this page: Glutamine RSS  |
| Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria | 20110251153 | 20111013 |
| According to the present invention, the prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which comprises a branched-chain amino acid such as valine, leucine or isoleucine or a salt thereof, a basic amino acid such as ornithine, arginine, lysine, histidine or citrulline or a salt thereof and glutamine or a salt thereof as active ingredients can be provided.
... |
| Immune enhancing compositions and methods of use thereof | 20110250240 | 20111013 |
| A method of administering parenterally, particularly intramuscularly, glutamine and cystine and glycine plus selenium; or lactalbumin plus selenium; or lactalbumin and glutamine and cystine and glycine plus selenium, through a long-acting pharmaceutically acceptable carrier to a patient. The method comprises injecting a mixture of glutamine, cystine, glycine, lactalbumin and selenium in order to maintain the mixture systemically or locally for a sufficient time period so as to maintain blood levels of glutathione within an improved therapeutic range.
... |
| Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof | 20110250220 | 20111013 |
| This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding... |
| Factor ix polypeptide mutant, its uses and a method for its production | 20110244550 | 20111006 |
| Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
... |
| Meganuclease variants cleaving a dna target sequence from a glutamine synthetase gene and uses thereof | 20110225664 | 20110915 |
| An 1-Cre1 variant, wherein one of the two 1-Cre1 monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated respectively from positions 28 to 40 and 44 to 77 of 1-Cre1, said variant being able to cleave a DNA target sequence from the Glutamine Synthetase gene. Use of said variant and derived products for improving expression system for the production of recombinant protein.
... |
| Interleukin-9 receptor mutants | 20110224406 | 20110915 |
| This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and... |
| Novel inhibitors | 20110224259 | 20110915 |
| The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
... |
| Novel inhibitors | 20110224254 | 20110915 |
| Novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
... |
Subscribe to updates on this page: Glutamine RSS |
| Transgenic algae engineered for higher performance | 20110217780 | 20110908 |
| The present disclosure relates to transgenic algae having increased growth characteristics, and methods of increasing growth characteristics of algae. In particular, the disclosure relates to transgenic algae comprising a glutamine phenylpyruvate transaminase transgene and to transgenic algae comprising a glutamine phenylpyruvate transaminase transgene and a glutamine synthetase
... |
| Method for producing hyaluronic acid | 20110207178 | 20110825 |
| It is intended to provide a simple method for producing hyaluronic acid at a high yield. Further, it is also intended to provide a method for producing hyaluronic acid in a short period of time. The invention provides a method for producing hyaluronic acid including a step of culturing a microorganism having the capability to produce hyaluronic acid and a step of adding glutamine and arginine to a culture medium during late logarithmic growth phase of the microorganism.
... |
| Compositions and methods for supporting heat shock protein function | 20110189312 | 20110804 |
| Compositions and methods for promoting or maintaining protein accretion in cells, particularly in skeletal muscle cells, by supporting heat shock protein function. The compositions comprise glutamine and additional components directed at enhancing the activity of heat shock proteins.
... |
| Process for obtaining purified pterostilbene and methods of use thereof | 20110144053 | 20110616 |
| The present invention relates to a process of extraction and purification of a stilbenoid, pterostilbene, from botanical sources. The process involves obtaining pterostilbene having high degree of purity and the present invention also relates to pure form of pterostilbene obtained. The invention also relates to complexing the pterostilbene with carriers such as cyclodextrin for improving its water solubility and bioavailability. The present invention also describes a process for inhibition of Histone Deacetylases using pterostilbene optionally along with a carrier, and a method of managing Poly Glutamine repeat disorders by the administration of pterostilbene optionally along with a carrier.
... |
| Bacterial glutamine synthetases and methods of use | 20110136200 | 20110609 |
| Compositions and methods for conferring herbicide resistance to and improving nitrogen utilization of bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a polypeptide that confers resistance or tolerance to herbicidal glutamine synthetase inhibitors are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated polynucleotides corresponding to herbicidal glutamine synthetase inhibitor-resistant polynucleotides are provided. Additionally, polypeptides corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated polynucleotides comprising a variant of SEQ ID NO:1, wherein the variant polynucleotide encodes a polypeptide that is resistant to inhibition by herbicidal glutamine synthetase inhibitor.
... |
| Rna polymerase mutant with improved functions | 20110136181 | 20110609 |
| Disclosed is a T7 RNA polymerase mutant having improved thermal stability and/or specific activity in comparison with wild-type T7-like bacteriophage RNA polymerase, wherein at least one amino acid residue corresponding to at least one of the amino acid residues selected from the group at least consisting of glutamine at position 768, lysine at position 179 and valine at position 685 of the amino acid sequence that composes wild-type T7 RNA polymerase shown in SEQ ID NO: 6, is substituted with another amino acid.
... |
| Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication | 20110118133 | 20110519 |
| The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
... |
| Mutated immunoglobulin-binding protein | 20110112276 | 20110512 |
| The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
... |
| Novel inhibitors | 20110092501 | 20110421 |
| wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
... |
| Methods of distinguishing between glutamine formed by cataplerosis or proteolysis | 20110079093 | 20110407 |
| The present invention relates to methods of distinguishing between glutamine formed by cataplerosis or proteolysis. Sample from a subject may be assayed for deuteriated glutamine (following administration of deuteriated water (2H2O) and an agent that promotes excretion of glutamine from the subject). The methods are useful in clinical settings (e.g. to test whether or not patients are suffering from proteolysis or whether athletes are abusing anabolic drugs); and may be adapted for screening test compounds for cataplerotic or proteolytic activity.
... |
| New l-glutamic acid and l-glutamine derivative (iii), use thereof and method for obtaining them | 20110064673 | 20110317 |
| The present invention relates to fluorinated glutamic acid (glutamate) and glutamine derivatives wherein the fluorine atom is 19F. The glutamic acid (glutamate) and glutamine derivatives are compound(s) of general Formula I, which encompasses all possible diastereoisomers and/or enantiomere derivatives or mixtures thereof.
... |
| Method for correcting intestinal glutamine synthetase deficiency | 20110059168 | 20110310 |
| The method includes steps of providing non-pathogenic glutamine-synthetase-producing bacteria, introducing the provided non-pathogenic glutamine-synthetase-producing bacteria into intestines, releasing the introduced non-pathogenic glutamine-synthetase-producing bacteria in the intestines in a predetermined time period, and normalizing serum level of free glutamate and halting continual flooding of free glutamate into the brain.
... |
| Cancer starvation therapy | 20110054019 | 20110303 |
| The present invention is a glutamine analogue which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
... |
| Copolyhydroxyalkylglutamines functionalised with hydrophobic groups, and uses thereof, especially in therapeutics | 20110044930 | 20110224 |
| The invention relates to novel biodegradable materials which are based on modified polyamino acids and which can be used for the vectorisation of active principle(s) (AP). The invention also relates to novel pharmaceutical, cosmetic, dietary or phytosanitary compositions based on said polyamino acids. The aim of the invention is to provide a novel polymer raw material which can be used for the vectorisation of active principles and which can optimally fulfil all required specifications in said area, namely: biocompatibility, biodegradability and the ability to become easily associated with many active principles or to solubilise said principles and to release same in vivo. Said aim is achieved with novel copolyhydroxyalkylglutamines comprising glutamine units and optionally glutamate units and bearing hydrophobic groups containing between 8 and 30 carbon... |
| Nucleic acids encoding plant glutamine phenylpyruvate transaminase (gpt) and uses thereof | 20110030104 | 20110203 |
| Glutamine phenylpyruvate transaminase (GPT) proteins, nucleic acid molecules encoding GPT proteins, and uses thereof are disclosed. Provided herein are various GPT proteins and GPT gene coding sequences isolated from a number of plant species. As disclosed herein, GPT proteins share remarkable structural similarity within plant species, and are active in catalyzing the synthesis of 2-hydroxy-5-oxoproline (2-oxoglutaramate), a powerful signal metabolite which regulates the function of a large number of genes involved in the photosynthesis apparatus, carbon fixation and nitrogen metabolism.
... |
| Transgenic plants with enhanced growth characteristics | 20110030089 | 20110203 |
| The invention relates to transgenic plants exhibiting dramatically enhanced growth rates, greater seed and fruit/pod yields, earlier and more productive flowering, more efficient nitrogen utilization, increased tolerance to high salt conditions, and increased biomass yields. In one embodiment, transgenic plants engineered to over-express both glutamine phenylpyruvate transaminase (GPT) and glutamine synthetase (GS) are provided. The GPT+GS double-transgenic plants of the invention consistently exhibit enhanced growth characteristics, with T0 generation lines showing an increase in biomass over wild type counterparts of between 50% and 300%. Generations that result from sexual crosses and/or selfing typically perform even better, with some of the double-transgenic plants achieving an astounding four-fold biomass increase over wild type plants.
... |
| Yeast mutant and yeast extract | 20110020528 | 20110127 |
| A natural yeast extract which is rich in glutamic acid and therefore has an impact at first taste. Further, provided is a yeast extract which is also rich in 5′-guanylic acid or 5′-inosinic acid and therefore has strong umami. Further, provided is a yeast mutant capable of accumulating a large amount of glutamic acid, glutamine and ribonucleic acid for obtaining such a yeast extract. A yeast mutant to which resistance to organic acids and analogues thereof has been imparted by inducing spontaneous mutation, accumulates a significant amount, i.e., 10% by weight or more of the total of free glutamic acid and glutamine in the cell, and further accumulates 5% by weight or more of a ribonucleic acid. The yeast extract produced by using this strain contains... |
| Q3 sparc deletion mutant and uses thereof | 20110009337 | 20110113 |
| The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature fault of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies.
... |
| Plant glutamine phenylpyruvate transaminase gene and transgenic plants carrying same | 20110004961 | 20110106 |
| The invention relates to transgenic plants exhibiting enhanced growth rates, seed and fruit yields, and overall biomass yields, as well as methods for generating growth-enhanced transgenic plants. In one embodiment, transgenic plants engineered to over-express glutamine phenylpyruvate transaminase (GPT) are provided.
... |
| Processes of making and using pharmaceutical formulations of antineoplastic agents | 20100331382 | 20101230 |
| In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.
... |
| Probe compounds for protein tyrosine phosphatase (ptp) and precursors thereof | 20100317831 | 20101216 |
| In Formula (I), A1 and A2 represent amino acids. The amino acids include leucine, phenylalanine, glutamic acid, lysine, alanine, arginine, aspartic acid, asparagine, citrulline, cysteine, cystine, glutamine, glycine, histidine, hydroxyproline, isoleucine, methionine, proline, serine, threonine, tryptophan, valine or a combination thereof. The invention also provides probe compound precursors for protein tyrosine phosphatases (PTPs).
... |
| Flour supplement compositions and methods for preparing wheat flour | 20100316764 | 20101216 |
| The present disclosure is directed to flour supplement compositions that contain transglutaminase and an amino acid selected from lysine, glutamine or a combination thereof. Additionally, the present disclosure is directed to flour-based food compositions or foodstuffs (e.g., breads, pastas, noodles, etc.) prepared with the supplement. The present disclosure is still further directed to methods for preparing wheat flour compositions by adding the supplement or alternatively by adding an amino acid selected from lysine, glutamine or a combination thereof and transglutaminase to flour used therein.
... |
| Methods and compositions for inactivating glutamine synthetase gene expression | 20100311124 | 20101209 |
| Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.
... |
| Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds | 20100298280 | 20101125 |
| The present invention relates to tetranortriterpenoid compounds and pharmaceutical compositions thereof, which are provided for use in the treatment, diagnosis and/or prevention of trinucleotide repeat disorders (like a polyglutamine diseases, e.g Huntingdon's disease), amyloid diseases, neurodegenerative disease, protein misfolding diseases or tumors. The tetranortriterpenoid compounds of the present invention are further provided for the reduction and/or inhibition of the aggregation of amyloidogenic proteins, preferably of polyglutamine proteins (such as huntingtin) as well as for increasing proteasome activity. The present invention furthermore relates to nucleic acids, comprising the nucleotide sequences of two huntingtin fragments, as well as to cells and kits, which are useful in methods for assessing the aggregation of huntingtin and in methods for identifying compounds, which modulate the aggregation of huntingtin.
... |
| Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof | 20100291559 | 20101118 |
| Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases, and orthogonal pairs of lysyl-tRNAs/synthetases, which incorporate homoglutamines into proteins are provided in response to a four base codon. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with homoglutamines using these orthogonal pairs.
... |
| Novel [f-18]-labelled l-glutamic acid and l-glutamine derivatives (i), their use and processes for their preparation | 20100290991 | 20101118 |
| What is described are the compounds and the synthesis of [F-18]-labelled L-glutamic acid, [F-18]-labelled L-glutamate, their derivatives of the formula (I) and their use.
... |
| Uses for aqueous streams containing proteins | 20100286034 | 20101111 |
| The present invention relates to a protein hydrolysate comprising free amino acids and peptides whereby the weight ratio of free amino acids to peptides is about 1:1 and wherein at least about 50 molar % of the peptides has a molecular weight of 400 Da or less. This composition may be rich in one or more branched-chain amino acid-(BCAA-) and or glutamine-containing di- or tripeptides. Also, the invention relates to the use of a water soluble protein-containing aqueous fraction obtained from a wet-milling process or the protein hydrolysate in: the manufacture of a medicament for the treatment or prevention of a condition associated with inappropriate blood sugar metabolism; aiding recovery and/or endurance during or after exercise; stimulating the generation of lean body mass; infant nutrition; or... |
| Expression construct for digesting aggregating protein and method of inhibiting the aggregation of aggregating protein | 20100279402 | 20101104 |
| It is intended to provide a means which is efficacious in digesting a protein forming aggregates in a eukaryotic cell such as mutant superoxide dismutase 1 or an androgen receptor having an abnormally extended polyglutamine chain. Namely, an expression construct for digesting an aggregating protein which has a nucleic acid encoding an archaeal proteasome and being connected in an operable manner to a promoter for eukaryotic cells. By transferring this expression construct into a eukaryotic cell, the aggregating protein is digested owing to the action of the archaeal proteasome.
... |
| Use of phosphoketolase for producing useful metabolites | 20100267094 | 20101021 |
| The present invention provides a bacterium which has an ability to produce a useful metabolite derived from acetyl-coenzyme A, such as L-glutamic acid, L-glutamine, L-proline, L-arginine, L-leucine, L-cysteine, succinate, and polyhydroxybutyrate, wherein said bacterium is modified so that activities of D-xylulose-5-phosphate phosphoketolase and/or fructose-6-phosphate phosphoketolase are enhanced. The present invention also provides a method for producing the useful metabolite using the bacterium.
... |
| Plant glutamine phenylpyruvate transaminase gene and transgenic plants carrying same | 20100263090 | 20101014 |
| The invention relates to transgenic plants exhibiting enhanced growth rates, seed and fruit yields, and overall biomass yields, as well as methods for generating growth-enhanced transgenic plants. In one embodiment, transgenic plants engineered to over-express glutamine phenylpyruvate transaminase (GPT) are provided.
... |
| Reducing post-operative adhesion formation with intraperitoneal glutamine | 20100260819 | 20101014 |
| Intraperitoneal administration of glutamine reduces post-operative adhesion formation.
... |
| Mucositis prevention supplement and treatment | 20100255119 | 20101007 |
| The present invention provides for a nutritional composition comprising from 0.25 g to 25 g of glutamine, in neutral or salt form or precursor or derivative thereof; and from 0.1 g to 10 g of a phytochemical or a mixture thereof, wherein the phytochemical is an antioxidant. The nutritional composition is particularly useful in the treatment and/or prevention of mucositis.
... |
| Wake-up remedy | 20100234308 | 20100916 |
| A wake-up remedy that for persons with the subjective symptoms of feeling languid after wake-up, having a hard time awaking, etc., relieves the symptoms and allows them to have a fulfilling life. There is provided a wake-up remedy containing alanylglutamine or its salt as an active ingredient.
... |
| Marker specific to an oxidative degradation of tissues containing type iii collagen, means and methods and kits for the diagnosis, monitoring or prognosis of pathologies targeted by this marker | 20100233737 | 20100916 |
| Novel peptide marker, specific to the oxidative degradation of tissues containing type III collagen, preferably to nitrosylation of the type III collagen. This marker is defined of at least one peptide sequence of 5 to 25 amino acids (AAs) including a sub-sequence QYDSYD in which at least one of the Ys is nitrosylated and Q corresponds not only to glutamine but also to pyroglutamic acid. This marker is simple, sensitive and reliable and expedites the clinical information for obtaining oxidative degradation of tissues containing type III collagen (O.D.T.Coll III) pathologies. This marker allows better monitoring, prognosis and treatment of the O.D.T.Coll III pathologies. This invention concerns also elements of detection of the marker, methods and kits which allow, on one hand, the early, reliable, efficient and... |
| Freeze-dried plasma formats for the trauma care field | 20100233671 | 20100916 |
| Disclosed are freeze-dried plasma formats specifically designed for the trauma care field. Blood plasma is subjected to a glucose removal step, a protein fraction up-concentration step and addition of stabilizers prior to freeze-drying. Preferable stabilizers are glutamine dipeptides, glutamine and glycine. The glutamine based formulation is added direct to plasma and serves three main purposes: 1) Increases stability of plasma proteins and stabilizes pH in freeze-dried state; 2) Increases stability of plasma proteins against Gamma Irradiation and thus allows for the application of a terminal sterilization step; 3) Introduces supplements beneficial to the trauma patient.
... |
| Dna comprising a dna seq. of isolated glucose isomerase | 20100228016 | 20100909 |
| This invention provides a series of recombinant Thermoanaerobacterium saccharolyticum glucose isomerases with improved catalytic activity and thermostability obtained by using recombinant techniques. These recombinant glucose isomerases comprise amino acid variation including phenylalanine (Phe) at position 139, alanine (Ala) at position 182, serine (Ser) at position 187, and glutamine (Gln) at position 299, and carry at least one additional mutated amino acid at position 87, position 217, position 260 or position 276, and possess a higher catalytic activity than that of the wild-type when using D-glucose as substrate. These recombinant glucose isomerases can be used for direct production of high fructose corn syrup containing 55% [wt] or higher concentration of fructose.
... |
| Methods of using isolated glucose isomerase | 20100227365 | 20100909 |
| This invention provides a series of recombinant Thermoanaerobacterium saccharolyticum glucose isomerases with improved catalytic activity and thermostability obtained by using recombinant techniques. These recombinant glucose isomerases comprise amino acid variation including phenylalanine (Phe) at position 139, alanine (Ala) at position 182, serine (Ser) at position 187, and glutamine (Gin) at position 299, and carry at least one additional mutated amino acid at position 87, position 217, position 260 or position 276, and possess a higher catalytic activity than that of the wild-type when using D-glucose as substrate. These recombinant glucose isomerases can be used for direct production of high fructose corn syrup containing 55% [wt] or higher concentration of fructose.
... |
| Cho-k1 cell line | 20100221781 | 20100902 |
| The current invention reports a CHO-K1 cell, characterized in that said CHO-K 1 cell is derived from CHO-K1 cell deposited as ATCC CCL-61, grows in suspension, requires no glutamine, no insulin, and no growth factors in the cultivation medium for growth, whereby said CHO-K1 cell is not modified compared to the deposited CHO-K1 cell ATCC CCL-61 cell line by the introduction, deletion, or inactivation of a nucleic acid. Also reported are a method for obtaining said CHO-K1 cell and a method for the production of a heterologous polypeptide using such a CHO-K1 cell according to the invention.
... |
| [f-18]-labeled l-glutamic acid, [f-18]-labeled l-glutamine, derivatives thereof and use thereof and processes for their preparation | 20100217011 | 20100826 |
| The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, their derivatives as set forth in formula (I) and their uses are described.
... |
| Polymorphs of n2-(1,1'-biphenyl-4-ylcarbonyl)-n1-[2-(4-fluorophenyl)-1,1-dimethylethyl]-l-alpha-glutamine | 20100216886 | 20100826 |
| Disclosed are novel polymorphic forms of N2-(1,1′-biphenyl-4-ylcarbonyl)-N1-[2-(4-fluorophenyl)-1,1-dimethylethyl]-L-α-glutamine, methods of preparing the polymorphic forms, compositions containing the polymorphic forms, and methods of treatment using the polymorphic forms.
... |
| Herbicidally active composition | 20100190794 | 20100729 |
| C) safeners.
... |
| Transgenic plants with enhanced growth characteristics | 20100186121 | 20100722 |
| The invention relates to transgenic plants exhibiting dramatically enhanced growth rates, greater seed and fruit/pod yields, earlier and more productive flowering, more efficient nitrogen utilization, increased tolerance to high salt conditions, and increased biomass yields. In one embodiment, transgenic plants engineered to over-express both glutamine phenylpyruvate transaminase (GPT) and glutamine synthetase (GS) are provided. The GPT+GS double-transgenic plants of the invention consistently exhibit enhanced growth characteristics, with T0 generation lines showing an increase in biomass over wild type counterparts of between 50% and 300%. Generations that result from sexual crosses and/or selfing typically perform even better, with some of the double-transgenic plants achieving an astounding four-fold biomass increase over wild type plants.
... |
| Materials and methods for treatment and diagnosis of disorders associated with oxidative stress | 20100184728 | 20100722 |
| The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention. In one... |
| Alkaline protease | 20100184188 | 20100722 |
| It is an object of the present invention to provide alkaline proteases having industrially sufficient protein productivity and a significant detergency. In the alkaline proteases, the amino acid residues at (a) position 9, (b) position 49, (c) position 194, (d) position 212, (e) position 237, (f) position 245, (g) position 281, (h) position 313, (i) position 379 and (j) position 427 in SEQ ID NO: 2 are selected from the following amino acid residues; Position (a); glutamine, Position (b); glutamine, Position (c); lysine or arginine, Position (d); arginine, asparagine or glutamine, Position (e); asparagines, Position (f); asparagines. Position (g); arginine, Position (h); asparagines, Position (i); lysine, arginine, glutamic acid or aspartic acid, and Position (j); arginine.
... |
| Method for production of l-glutamine | 20100184163 | 20100722 |
| A polypeptide comprising an amino acid sequence in which one or more amino acids are deleted, substituted or added in the amino acid sequence of a glutamine synthetase 2 derived from a microorganism belonging to a coryneform bacterium, wherein the coryneform bacterium producing the polypeptide has L-glutamine productivity, a DNA encoding the polypeptide, a recombinant DNA comprising the DNA, a microorganism comprising the DNA or the recombinant DNA, and a process for producing L-glutamine using the microorganism are provided.
... |
| Methods for manufacturing amino acid mimetic copolymers and use of same | 20100183798 | 20100722 |
| A method of using a biocompatible polymer is used. Biocompatible polymers are manufactured to include an ammo acid mimetic monomer and one or more hydrophobic acrylate monomers. The amino acid mimetic monomers are selected to mimic the side chain of the amino acids asparagine or glutamine. The amino acid mimetic monomer can be a methacryloyl or acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide, or glycinamide. These amide functional groups offer the advantage of moderate hydrophilicity with little chemical reactivity. The amino acid mimetic monomer can be copolymerized with one or more hydrophobic acrylate monomers to obtain desired coating properties.
... |
| Body fluid expanders comprising n-substituted aminosulfonic acid buffers | 20100183747 | 20100722 |
| A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The non-phosphate buffer may be a physiologically acceptable N-substituted aminosulfonic acid buffers, especially those having a pKa value in aqueous solution of from 7.1 to 7.5 at 2O0C, and most preferably N-tris(hydroxymethyl) methyl-2-aminoethanesulfonic acid (TES), 3-(N-morpholino) propanesulfonic acid (MOPS), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) and combinations thereof. Preferred components include from 100 to 150 (preferably about 135) mmoles/L sodium ions, from 2.5 to 6.2 (preferably about 5) mmoles/L potassium ions, from 0.1 to 2.5 (preferably about 1.25) mmoles/L calcium ions, from 0.4 to 25.0 (preferably about 0.45) mmoles/L magnesium ions, from 96... |
| Systems and methods for making hepatocytes from extrahepatic somatic stem cells and use thereof | 20090317365 | 20091224 |
| A method for making hepatocytes from extrahepatic somatic stem cells comprises: a) culturing somatic stem cells in a medium comprising hepatic growth factor to cause the stem cells to differentiate toward hepatocytes; b) culturing cells from a) in a medium comprising HGF and oncostatin M to facilitate the cell differentiation toward hepatocytes; and c) culturing cells from b) in a medium comprising oncostatin M to cause the differentiated cells to mature into hepatocytes, thereby producing a cell population that has morphological features of hepatocytes and at least four of the following characteristics: i) antibody-detectable expression of albumin; ii) real-time reverse transcriptase-polymerase chain reaction-detectable expression of α-fetoprotein, HNF-1α, HNF-3β, HNF-4, HNF-6, α1-antitrypsin, alkaline phosphatase, tryptophan 2,3-dioxygenase, tyrosine aminotransferase, cytochrome P450 family 2 subfamily E polypeptide 1, glutamine... |
| Medicament for use in connection with cartilage impairment | 20090312427 | 20091217 |
| Use of a substance for treating medical joint conditions, e.g. arthrosis, rheumatoid arthritis and cartilage impairment. The use includes the use of alpha-ketoglutaric acid, glutamine or glutamic acid, as well as salts, amides, di- or tripeptides of the mentioned substances.
... |
| Superparamagnetic nanoparticles based on iron oxides with modified surface, method of their preparation and application | 20090309597 | 20091217 |
| The preparation of labelled cells proceeds by adding to the complete culture medium 5-20 μl, to advantage 10 μl, of a colloid containing 0.05-45 mg iron oxide per ml, to advantage 1-5 mg iron oxide per ml of the medium, and culturing the cells for a period of 1-7 days, to advantage for 1-3 days, at 37° C. and 5% of CO2.
... |
| Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria | 20090306208 | 20091210 |
| According to the present invention, the prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria which comprises a branched-chain amino acid such as valine, leucine or isoleucine or a salt thereof, a basic amino acid such as ornithine, arginine, lysine, histidine or citrulline or a salt thereof and glutamine or a salt thereof as active ingredients can be provided.
... |
| Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same | 20090306209 | 20091210 |
| Oral amino acid formulations comprising polyethylene glycol are enteric coated. Most preferred amino acids are leucine, glutamine, and arginine. The most preferred polyethylene glycols have an average molecular weight of from 3150 to 3685, although for particular formulation formulations and particular uses, the average molecular weight polyethylene glycols may range from 190 to 9000.
... |
| Method of controlling plants | 20090305890 | 20091210 |
| A method of controlling plants that are resistant to paraquat or glufosinate, the method comprising applying to the plants or to a locus of the plants a synergistic combination of a PS1 inhibitor and glutamine synthetase inhibitor.
... |
| Immortal unipotent porcine picm-19h and picm-19b stem cell lines | 20090291064 | 20091126 |
| Two cell lines, PICM-19H and PICM-19B, were derived from the bipotent ARS-PICM-19 pig liver stem cell line and assessed for their potential application in artificial liver devices. The study included assessments of growth rate and cell density in culture, morphological features, and hepatocyte detoxification functions, i.e., inducible CYP450 activity, ammonia clearance, and urea production. The PICM-19H cells contain numerous mitochondria, Golgi apparatus, smooth and rough endoplasmic reticulum, vesicular bodies and occasional lipid vacuoles. PICM-19H cells display inducible CYP450 activity, clear ammonia, and produce urea in a glutamine-free medium. Ultrastructural analysis of the PICM-19B monolayers show that the roughly cuboidal cells display basal-apical polarization and are joined by tight junction-like complexes. Other ultrastructure features are similar to those of PICM-19H cells except that they possess numerous cell... |
| Prophylactic/therapeutic agent for neurodegenerative disease | 20090280488 | 20091112 |
| (b) a protein having an amino acid sequence resulting from deletion, substitution, addition or insertion of one or more amino acids in the amino acid sequence of SEQ ID NO: 2, 4, 6 or 8 and having binding activity to an abnormal polyglutamine protein produced in a neurodegenerative disease.
... |
| Prophylactic/therapeutic agent for neurodegenerative disease | 20090280488 | 20091112 |
| (b) a protein having an amino acid sequence resulting from deletion, substitution, addition or insertion of one or more amino acids in the amino acid sequence of SEQ ID NO: 2, 4, 6 or 8 and having binding activity to an abnormal polyglutamine protein produced in a neurodegenerative disease.
... |
| Method of enhancing electrotransport polypeptide flux by amino acid substitution with histidine | 20090275877 | 20091105 |
| Methods of modifying polypeptide drugs in order to enhance their transdermal electrotransport flux are provided. The polypeptide is modified by substituting a histidine residue (His) for one or more glutamine (Gln), threonine (Thr) and/or asparagine (Asn) residue(s). The His for Gln substitution is particularly preferred from the standpoint of retaining biological activity of the parent polypeptide. Compositions containing the modified polypeptide, which are useful for transdermal electrotransport delivery, are also provided.
... |
| Method of enhancing electrotransport polypeptide flux by amino acid substitution with histidine | 20090275877 | 20091105 |
| Methods of modifying polypeptide drugs in order to enhance their transdermal electrotransport flux are provided. The polypeptide is modified by substituting a histidine residue (His) for one or more glutamine (Gln), threonine (Thr) and/or asparagine (Asn) residue(s). The His for Gln substitution is particularly preferred from the standpoint of retaining biological activity of the parent polypeptide. Compositions containing the modified polypeptide, which are useful for transdermal electrotransport delivery, are also provided.
... |
| Compositions and methods for treating polyglutamine-expansion neurodegenerative diseases | 20090252717 | 20091008 |
| The invention relates to methods for stimulating fast axonal transport in polyglutamine expansion diseases and treating polyglutamine expansion diseases by inhibiting SAPK-dependent phosphorylation of kinesin. The present invention also provides methods for identifying agents which inhibit the phosphorylation of the kinesin, as well as methods for monitoring treatment of a polyglutamine expansion disease based on the phosphorylation of serine 176 of kinesin-1A or kinesin-1C, or serine 175 of kinesin-1B.
... |
| Compositions and methods for treating polyglutamine-expansion neurodegenerative diseases | 20090252717 | 20091008 |
| The invention relates to methods for stimulating fast axonal transport in polyglutamine expansion diseases and treating polyglutamine expansion diseases by inhibiting SAPK-dependent phosphorylation of kinesin. The present invention also provides methods for identifying agents which inhibit the phosphorylation of the kinesin, as well as methods for monitoring treatment of a polyglutamine expansion disease based on the phosphorylation of serine 176 of kinesin-1A or kinesin-1C, or serine 175 of kinesin-1B.
... |
| Method for production of a bioengineered form of tissue plasminogen activator | 20090246188 | 20091001 |
| The present invention relates to the recombinant method used for the production of soluble form of human tissue plasminogen activator variant. In this variant the threonine at position 103 of the endogenous tissue plasminogen activator is replaced by an asparagine leading to a new glycosylation site. At position 117 of the endogenous tissue plasminogen activator asparagine has been replaced by glutamine, leading to the removal of an N linked glycosylation site. At position 296-299 the amino acids lysine, histidine, arginine, and arginine have been replaced by four alanine amino acids. The invention further relates to the de novo synthesis of the nucleic acid sequence encoding tissue plasminogen activator, transformation of the constructed nucleic acid sequences into competent bacteria and sub-cloning of the same into mammalian expression... |
| Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal | 20090238895 | 20090924 |
| The invention dissolves the problem of the pharmaceutical preparation being a factor stimulating the absorption of microelements. The essence of the invention is that the preparation contains alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine of alpha-keto-glutarate, dipeptide of glutamine and other amino acids or/and tripeptides of glutamine and other amino acids or/and glutamate with other amino acid or/and salts of alpha-keto-glutarate or/and glutamine or/and glutamate or/and ornithine of alpha-keto-glutarate, dipepetides of glutamine or glutamate with other amino acid in a dose 0.01-0.5 g/kg/day and administered orally stimulates the absorption of iron, zinc, copper, manganese, strontium, calcium, phosphorus and other microelements from the alimentary canal to the blood ensuring proper—physiological—curative level of these compounds in the blood of people and animals.
... |
| Polyene antibiotics, compositions containing said antibiotics, method and micro-organisms used to obtain same and applications thereof | 20090221520 | 20090903 |
| The invention relates to novel polyenes having formula (I), wherein: R1 represents alkyl C1-C3; and R2 represents a functional group selected from CH3— or CONH2— (methyl- or primary amide-). The aforementioned polyenes have a biocide action on organisms comprising cell membranes that contain ergosterol, e.g., fungi or parasites. Said compounds can be obtained using a method that consists in cultivating a producing micro-organism under conditions that enable the production thereof. In addition, the invention also relates to a mechanism for the in vitro production of amidated polyenes, consisting in incubating carboxylated polyenes with cell-free extracts (or proteinaceous fractions) of the producers of same in the presence of ATP/Mg++ and an amide- group donor compound (preferably glutamine).
... |
| Composition and method for providing glutamine | 20090215900 | 20090827 |
| A process for preparing a glutamine-supplemented food product by contacting water and a nutritive base that pre-dominantly comprises meat and carbohydrate with a peptide source of glutamine to form a wet mixture and heating the wet mixture at a temperature of from about 50° C. to about 105° C. for a time sufficient to cook the nutritive base. The process forms a cooked food composition comprising from about 60% to about 85% by weight water. The product is useful for feeding to an animal to increase glutamine absorption or to strengthen immune function.
... |
| Composition and method for providing glutamine | 20090215900 | 20090827 |
| A process for preparing a glutamine-supplemented food product by contacting water and a nutritive base that pre-dominantly comprises meat and carbohydrate with a peptide source of glutamine to form a wet mixture and heating the wet mixture at a temperature of from about 50° C. to about 105° C. for a time sufficient to cook the nutritive base. The process forms a cooked food composition comprising from about 60% to about 85% by weight water. The product is useful for feeding to an animal to increase glutamine absorption or to strengthen immune function.
... |
| Composition and method for providing glutamine | 20090215900 | 20090827 |
| A process for preparing a glutamine-supplemented food product by contacting water and a nutritive base that pre-dominantly comprises meat and carbohydrate with a peptide source of glutamine to form a wet mixture and heating the wet mixture at a temperature of from about 50° C. to about 105° C. for a time sufficient to cook the nutritive base. The process forms a cooked food composition comprising from about 60% to about 85% by weight water. The product is useful for feeding to an animal to increase glutamine absorption or to strengthen immune function.
... |
| Composition and method for providing glutamine | 20090215900 | 20090827 |
| A process for preparing a glutamine-supplemented food product by contacting water and a nutritive base that pre-dominantly comprises meat and carbohydrate with a peptide source of glutamine to form a wet mixture and heating the wet mixture at a temperature of from about 50° C. to about 105° C. for a time sufficient to cook the nutritive base. The process forms a cooked food composition comprising from about 60% to about 85% by weight water. The product is useful for feeding to an animal to increase glutamine absorption or to strengthen immune function.
... |
| Composition and method for providing glutamine | 20090215900 | 20090827 |
| A process for preparing a glutamine-supplemented food product by contacting water and a nutritive base that pre-dominantly comprises meat and carbohydrate with a peptide source of glutamine to form a wet mixture and heating the wet mixture at a temperature of from about 50° C. to about 105° C. for a time sufficient to cook the nutritive base. The process forms a cooked food composition comprising from about 60% to about 85% by weight water. The product is useful for feeding to an animal to increase glutamine absorption or to strengthen immune function.
... |
| method for treating polyglutamine expansion neurodegenerative diseases | 20090208455 | 20090820 |
| The present invention relates to use of an inducer of Promyelocytic Leukemia protein (PML) expression, and especially PML IV for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases. More specifically, the present invention relates to the use of an interferon polypeptide for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases.
... |
| Novel uses for drugs targeting glutamine synthetase | 20090209474 | 20090820 |
| The present invention relates to novel therapeutic uses of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof. Furthermore, the present invention relates to the use of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof, in obtaining methods of screening and of developing drugs. Finally, the present invention relates to the novel therapeutic use of other glutamine synthetase (GS) ligands and to the use of these ligands in obtaining methods for screening and developing drugs.
... |
| Colonic delivery therapeutic agents for inflammatory bowel disease | 20090209503 | 20090820 |
| The present invention discloses a therapeutic agent for inflammatory bowel disease, which is in the from of delivering 1 to 5 g of glutamine to the large intestine per one administration; and the therapeutic agent for inflammatory bowel disease with which an anti-inflammatory agent(s) is combined. This therapeutic agent for inflammatory bowel disease can safely and effectively treat inflammatory bowel disease including ulcerative colitis without increasing the frequency of bowel movements.
... |
| Glutamine-containing compositions and a method for increasing blood flow using same | 20090209614 | 20090820 |
| The present invention provides a glutamine-containing composition which functions to increase blood flow. Glutamine is present in the composition in an amount of 25 mg/kg body weight to 150 mg/kg body weight. By administering the composition to a subject in need thereof, the blood flow in the capillary vessels can be efficiently increased, while inhibiting any side effects such as low blood pressure. The present invention also provides food or feed containing the composition for increasing blood flow.
... |
| method for treating polyglutamine expansion neurodegenerative diseases | 20090208455 | 20090820 |
| The present invention relates to use of an inducer of Promyelocytic Leukemia protein (PML) expression, and especially PML IV for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases. More specifically, the present invention relates to the use of an interferon polypeptide for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases.
... |
| Novel uses for drugs targeting glutamine synthetase | 20090209474 | 20090820 |
| The present invention relates to novel therapeutic uses of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof. Furthermore, the present invention relates to the use of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof, in obtaining methods of screening and of developing drugs. Finally, the present invention relates to the novel therapeutic use of other glutamine synthetase (GS) ligands and to the use of these ligands in obtaining methods for screening and developing drugs.
... |
| Colonic delivery therapeutic agents for inflammatory bowel disease | 20090209503 | 20090820 |
| The present invention discloses a therapeutic agent for inflammatory bowel disease, which is in the from of delivering 1 to 5 g of glutamine to the large intestine per one administration; and the therapeutic agent for inflammatory bowel disease with which an anti-inflammatory agent(s) is combined. This therapeutic agent for inflammatory bowel disease can safely and effectively treat inflammatory bowel disease including ulcerative colitis without increasing the frequency of bowel movements.
... |
| Glutamine-containing compositions and a method for increasing blood flow using same | 20090209614 | 20090820 |
| The present invention provides a glutamine-containing composition which functions to increase blood flow. Glutamine is present in the composition in an amount of 25 mg/kg body weight to 150 mg/kg body weight. By administering the composition to a subject in need thereof, the blood flow in the capillary vessels can be efficiently increased, while inhibiting any side effects such as low blood pressure. The present invention also provides food or feed containing the composition for increasing blood flow.
... |
| Blood-viscosity reducing agent | 20090202982 | 20090813 |
| A blood-viscosity reducing agent contains a protein derived from Bacillus subtilis natto and including, sequentially from an amino group terminal, a first structural amino acid sequence having alanine, threonine, aspartic acid, glycine, valine, glutamic acid, tryptophan, asparagine, valine, aspartic acid, glutamine, isoleucine, aspartic acid, alanine, proline, lysine, alanine, tryptophan, alanine, leucine, glycine, tyrosine aspartic, acid, glycine, threonine, glycine, threonine, valine, valine, alanine, serine, isoleucine, aspartic acid, threonine, glycine, valine, glutamic acid, tryptophan, asparagine, histidine, proline, alanine, leucine, lysine, glutamic acid, lysine, tyrosine, arginine, glycine, tyrosine, asparagine, proline, glutamic acid, asparagine, proline, asparagine, glutamic acid, proline, glutamic acid, asparagine, glutamic acid, methionine, asparagine, tryptophan, tyrosine, aspartic acid, alanine, valine, alanine, glycine, glutamic acid, alanine, serine, proline, tyrosine, aspartic acid, aspartic acid, leucine, alanine, histidine, glycine, threonine, histidine,... |
| Ammonia-specific 5'-xmp aminase mutant | 20080318278 | 20081225 |
| Disclosed herein are ammonia-specific 5′-XMP aminase mutants and a method for preparing the same. A mutation is introduced into the active site of glutamine-dependent catalysis in 5′-XMP aminase. The resulting 5′-XMP aminase mutant is devoid of the glutamine-dependent activity and specifically reacts with external ammonia in converting 5′-XMP into 5′-GMP. Thus, the ammonia-specific 5′-XMP aminase mutant is stabler within cells compared to the wild type, and can be useful in the industrial conversion of 5′-XMP into 5′-GMP.
... |
| Colonic delivery therapeutic agents for inflammatory bowel disease | 20080319073 | 20081225 |
| The present invention discloses a therapeutic agent for inflammatory bowel disease, which is in the from of delivering 1 to 5 g of glutamine to the large intestine per one administration; and the therapeutic agent for inflammatory bowel disease with which an anti-inflammatory agent(s) is combined. This therapeutic agent for inflammatory bowel disease can safely and effectively treat inflammatory bowel disease including ulcerative colitis without increasing the frequency of bowel movements.
... |
| Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist | 20080312160 | 20081218 |
| A therapeutic method for treating intestinal damage, enteritis, diarrhea, or a combination thereof caused by a C. difficile is provided. The method includes administration to a patient in need thereof an effective amount of an A2A adenosine receptor agonist, optionally in combination with an effective amount of a stable glutamine derivative, e.g., alanyl-glutamine.
... |
| Glucose isomerase mutants, dna thereof and use thereof | 20080305529 | 20081211 |
| This invention provides a series of recombinant Thermoanaerobacterium saccharolyticum glucose isomerases with improved catalytic activity and thermostability obtained by using recombinant techniques. These recombinant glucose isomerases comprise amino acid variation including phenylalanine Phe) at position 139, alanine (Ala) at position 182, serine (Ser) at position 187, and glutamine (Gln) at position 299, and carry at least one additional mutated amino acid at position 87, position 217, position 260 or position 276, and possess a higher catalytic activity than that of the wild-type when using D-glucose as substrate. These recombinant glucose isomerases can be used for direct production of high fructose corn syrup containing 55.% [wt] or higher concentration of fructose.
... |
| Palatability enhancing compositions and foods for pets, and methods regarding the same | 20080299286 | 20081204 |
| Palatability enhancing compositions for pet foods, and pet foods with increased palatability, are provided. In some embodiments, the compositions and pet foods contain tea, such as green tea. In some embodiments, the compositions and pet foods contain brewer's yeast, liver hydrolysate, phosphate, and green tea. Shrimp meal and Tuna meal can also be utilized in these embodiments. In some embodiments, the compositions and pet foods comprise an ingredient having at least one of theanine; glutamine; tea; 1,5 octadien-3 one; 1,5-octadien-3-ol; and Camellia sinensis plant. In one example, green tea is used in a pet food palatability enhancing system at 0.1-25%, 1-15%, or 2-9% by weight of the system, and at 0.025-0.5% or 0.01 to 1.0% by weight of the pet food.
... |
| Process for the preparation of n(5)-ethylglutamine | 20080234508 | 20080925 |
| Disclosed relates to a process for preparing N(5)-ethylglutamines economically without a specific purification process via a simplified and safe process, in which glutamic acid derivatives, represented by formula 1, protected by phthaloyl groups react with ethylamine to cause an amidation and a deprotection reaction in turn under the same reaction condition, thus preparing N(5)-ethylglutamines.
... |
| Personal care composition | 20080206169 | 20080828 |
| Personal care composition comprising at least one skin care active selected from the group consisting of acetyl glutamic acid, acetyl glutamine, acetyl methionine, acetyl tributyl citrate, acetyl triethyl citrate, acetyl tyrosine, adipic acid, alanine, arginine, arginine glutamate, benzophenone-3, camphor, gluconolactone, glucose, glycine, histidine hydrochloride, hydroxyproline, maltitol, phenylalanine, succinic acid, buffered lactic acid, tris(tetramethylhydroxypiperidinol) citrate, a boswellic acid compound, and salts, isomers, derivatives, and mixtures of any of the foregoing; and a dermatologically acceptable carrier.
... |
| Therapeutic delivery system comprising a high molecular weight peg-like compound | 20080206188 | 20080828 |
| The present invention provides a system for delivering a wide range of chemical and biological therapeutics, including protein therapeutics, via transepithelial routes. The system comprises a high molecular weight polyethylene glycol-like (HMW PEG-like) compound for use with a therapeutic compound. Optionally, the system comprises a composition containing one or more HMW PEGlike compounds and one or more therapeutics, supplemented with a protective polymer such as dextran and/or essential pathogen nutrients such as L-glutamine. Administered alone, the HMW PEG-like compounds also provide therapeutic benefits. Also provided are methods for preventing or treating epithelial diseases, disorders, or conditions, such as an epithelium at risk of developing gut-derived sepsis attributable to an intestinal pathogen, as well as methods for monitoring the administration of HMW PEG-like compounds.
... |
| Enzyme composition for improving food digestion | 20080199448 | 20080821 |
| An orally administered composition for improving food absorption and digestion contains therapeutically effective dosages of digestive enzymes and L-glutamine as active ingredients. The digestive enzymes include at least one each of a lipase, a protease, and an amylase, and at least a portion of each of these enzymes is enteric coated.
... |
| Protein and preventive/remedy for neurodegenerative diseases such as polyglutamine diseases by utilizing the same | 20080188408 | 20080807 |
| (b) A protein including an amino acid sequence in which one to several amino acids are deleted, substituted or added in the amino acid sequence of (a), the protein having a dominant negative effect on a transcriptional activation factor YAP.
... |
| Q3 sparc deletion mutant and uses thereof | 20080182258 | 20080731 |
| The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature form of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies.
... |
| Combinatorial artificial receptors including peptide building blocks | 20080182270 | 20080731 |
| R6 can be hydrogen or any suitable blocking or protecting group for an carboxyl-terminal carboxyl group of a peptide. Suitable blocking or protecting groups include those described in Green, T W; Wuts, PGM (1999), Protective Groups in Organic Synthesis Third Edition, Wiley-Interscience, New York, 779 pp. In an embodiment, R6 is hydrogen. In an embodiment, R6 is —XR10, in which X is a heteroatom such as N, O, or S and R10 is lower (e.g., C1 to C6) alkyl, substituted lower (e.g., C1 to C6) alkyl, aryl, substituted aryl, or the like. In an embodiment, R6 is —NHCH3.
... |
| Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy | 20080182775 | 20080731 |
| It is intended to provide a model animal faithfully reproducing the pathogenic conditions of spinal and bulbar muscular atrophy, a method of screening a remedy for polyglutamine disease using the same, and a remedy for spinal and bulbar muscular atrophy. Namely, a nonhuman animal having the following characteristics (1) to (5) in its conditions or pathological findings: (1) showing progressive myoatrophy; (2) showing lowering in muscular power; (3) in immunostaining with the use of an anti-polyglutamine antibody, showing nuclear diffuse staining and nuclear inclusions; (4) in immunostaining with the use of an anti-androgen receptor antibody, showing nuclear diffuse staining and nuclear inclusions; and (5) showing a neurogenic change. A remedy for polyglutamine disease is screened by administering a test substance to this nonhuman animal and examining... |
| Metabotropic glutamate receptor activator | 20080182811 | 20080731 |
| Amino acids other than glutamic acid are used as a metabotropic glutamate receptor activator. More preferably, aspartic acid, valine and cysteine are used as a group I metabotropic glutamate receptor activator; alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ornithine, taurine and hydroxyproline are used as a group II metabotropic glutamate receptor activator; and cysteine is used as a group III metabotropic glutamate receptor activator.
... |
| Alkaline protease | 20080177040 | 20080724 |
| The present invention makes it possible to efficiently produce and provide alkaline proteases having activity even in the presence of a highly concentrated fatty acid, and exhibiting excellent detergency for the removal of a complex stain containing protein, sebum and the like, and therefore being useful as an enzyme to be incorporated in a detergent.
... |
| Stable differentiation of adult stem cells | 20080160614 | 20080703 |
| A method of differentiating adult stem cells, such as those derived from a teratocarcinoma cell line, the Ntera2/D1 clone (NT2). The developed cells exhibit a stable neurotransmitter phenotype without the required use of growth factors or retinoic acid in differentiation process, which may be difficult to completely remove during commercial production. An identification of specific neurotransmitters is possible in these differentiated NT2-derived neurons (NT2-N) after 30 days in culture or 30 days survival in vivo. The invention includes a method to stably differentiate neuronal stem/precursor cells to a neuronal phenotype for use in cell replacement therapy for neurodegenerative disease, stroke or spinal cord injury. At least four different types of neurons are produced from this method of differentiation: dopaminergic, cholinergic, GABAergic and glutaminergic. Additionally, since the... |
| Amino acid composition | 20080161380 | 20080703 |
| The present invention herein provides an amino acid composition which consists essentially of (1) glycine, (2) at least one member selected from the group consisting of proline and alanine, and (3) at least one member selected from the group consisting of glutamine and glutamic acid; as well as such an amino acid composition which further comprises at least one member selected from the group consisting of CoA, acetyl CoA, and pyruvic acid. This amino acid composition has an effect of accelerating the combustion of the body fat.
... |
| Method for the production of biomass from plant differentiated tissue | 20080153165 | 20080626 |
| The present invention provideS a method and a culture medium for the production of food biomass by directly culturing seed kernel tissue, or seed cotyledonary differentiated tissue. The culture medium of the present invention contains at least DKW culture medium, Vitamin MS culture medium with an enriched concentration of thiamine, sacarose, kinetine, adenine, 2,4diclorofenoxiacetico (2,4D), L-Glutamine, cysteine, ascorbic acid, and Gelrite®.
... |
| Therapeutic nutrient compositions or combinations and methods of their use | 20080131525 | 20080605 |
| The invention may be summarized as follows. A combination to be parenterally delivered to a critically ill patient or for the purpose of improving mitochondrial function. The combination comprises a glutamine precursor molecule and an antioxidant in sufficient concentrations to be clinically effective. The combination may be prepared in the absence of lipids or carbohydrates. The combination may be prepared in small volumes to benefit volume restricted patients. A composition, or a unit dosage form comprising the combination and methods of administering the combination, composition or unit dosage form are also provided.
... |
| Recombinant murine leukemia virus reverse transcriptases, the genes encoding and the method for expressing it | 20080131950 | 20080605 |
| This invention provides recombinant murine leukemia virus reverse transcriptases, genes encoding these proteins and expression methods. The said murine leukemia virus reverse transcriptases are a series of MLV-RT proteins wherein the 84th amino acid residue (Q84) from the N-terminus is replaced with amino acid X, which is an amino acid with a side chain shorter than glutamine. The said murine leukemia virus reverse transcriptases have higher enzyme activity and processivity than the wild type enzyme, and are expected to be widely used in the field of biotechnology for cDNA synthesis.
... |
| Methods for manufacturing amino acid mimetic copolymers and use of same | 20080124450 | 20080529 |
| Biocompatible polymers are manufactured to include an amino acid mimetic monomer and one or more hydrophobic acrylate monomers. The amino acid mimetic monomers are selected to mimic the side chain of the amino acids asparagine or glutamine. The amino acid mimetic monomer can be a methacryloyl or acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide, or glycinamide. These amide functional groups offer the advantage of moderate hydrophilicity with little chemical reactivity. The amino acid mimetic monomer can be copolymerized with one or more hydrophobic acrylate monomers to obtain desired coating properties.
... |
| Amino acid mimetic copolymers and medical devices coated with the copolymers | 20080125514 | 20080529 |
| Biocompatible polymers are manufactured to include an amino acid mimetic monomer and one or more hydrophobic acrylate monomers. The amino acid mimetic monomers are selected to mimic the side chain of the amino acids asparagine or glutamine. The amino acid mimetic monomer can be a methacryloyl or acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide, or glycinamide. These amide functional groups offer the advantage of moderate hydrophilicity with little chemical reactivity. The amino acid mimetic monomer can be copolymerized with one or more hydrophobic acrylate monomers to obtain desired coating properties.
... |
| Composition for recovery from or prevention of central nervous system fatigue | 20080114067 | 20080515 |
| A composition for recovery from or prevention of central nervous system fatigue (brain fatigue), comprising as active ingredients at least any amino acid selected from the group consisting of tyrosine, methionine, phenylalanine and glutamine, especially methionine and phenylalanine together with a branched chain amino acid of L-valine, L-leucine or L-isoleucine. This composition is provided as an injection agent or fluid infusion, or as, through addition of an appropriate vehicle such as starch or lactose, a solid dosable form (pharmaceutical application) such as tablets, granules or powder, or as any of various drinking water forms (food application) such as those known as health drink.
... |
| Glycolysis-inhibiting substances in cell culture | 20080108106 | 20080508 |
| An improved system for large scale production of proteins and/or polypeptides in cell culture is provided. In accordance with the present invention, cells expressing the protein or polypeptide of interest are grown in media that comprise a glycolysis-inhibiting substance. Additionally and/or alternatively, cells expressing the protein or polypeptide of interest are grown in media in which glutamine is limited. The use of such a system allows high levels of protein or polypeptide production and lessens accumulation of undesirable metabolic waste products such as lactate. Proteins and polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, immunogenic, agricultural or other commercial compositions.
... |
| Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor | 20080108684 | 20080508 |
| Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-α. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-α production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.
... |
| Compositions and methods for transdermal joint pain therapy | 20080102107 | 20080501 |
| Compositions suitable for use in treating pain and increasing range of motion of an affected joint of an animal, particularly a human. The compositions contain a transdermal delivery formulation for delivering effective amounts of glutamine, hyaluronic acid, methysulfonylmethane, and glucosamine to the affected joint. The compositions are applied topically to the skin area adjacent to the affected joint. Methods for treating pain and increasing range of motion that use the transdermal joint pain therapy compositions are also provided.
... |
| Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication | 20080102467 | 20080501 |
| The invention provides a method of screening patients to identify those patients more likely to exhibit an increased risk of treatment-emergent suicidal ideation comprising: (a) obtaining a sample of genetic material from the patients, and (b) assaying the sample for the presence of a genotype in the patients which is associated with an increased risk of treatment-emergent suicidal ideation, wherein the genotype is characterized by a polymorphism in a gene selected from the group consisting of glutamine receptor, ionotropic, kainate 2 (GRIK2); glutamate receptor ionotropic AMPA 3 (GRIA3); and combinations thereof.
... |
| Asparaginases and method of preparing a heat-treated product | 20080095883 | 20080424 |
| The formation of acrylamide during heat treatment in the production of a food product is reduced by treating the raw material with an enzyme before the heat treatment. The enzyme is capable of reacting on asparagine or glutamine (optionally substituted) as a substrate or is a laccase or a peroxidase.
... |
| Plating solution of palladium alloy and method for plating using the same | 20080073218 | 20080327 |
| The present invention relates to a plating solution of palladium alloy and has an object to provide a plating solution of palladium alloy highly stable and capable of stably forming a plated film of a given alloy composition. The present invention relates to a plating solution of palladium alloy containing a palladium complex and a metal salt, wherein the palladium complex is coordinated with at least one neutral amino acid selected from the group consisting of glycine, alanine, valine, leucine, serine, threonine, asparagine, glutamine and tyrosine as a ligand.
... |
| Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents | 20080076811 | 20080327 |
| The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus,... |
| Method for identifying jnk and mlk inhibitors for treatment of neurological conditions | 20070298442 | 20071227 |
| The present invention describes methods for identifying compounds that inhibit JNK and MLK kinase activity as drugs for treating a mammal susceptible to or having a neurological condition. This invention also discloses methods for preventing neuronal cell death and treating neurological conditions that involve neuronal cell death, particularly neurodegenerative diseases characterized by glutamine or kainate mediated toxicity, such as Huntington's disease and Alzheimer's disease.
... |
| Pharmaceutical composition and method for the transdermal delivery of calcium | 20070292493 | 20071220 |
| The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel. In addition to calcium, the transdermal pharmaceutical composition may also contain a therapeutically effective amount of: (1) a pharmaceutically acceptably salt of other minerals such as magnesium, zinc, selenium, manganese, or chromium; (2) a vitamin such as vitamin A, vitamin D, vitamin C, vitamin E or B-complex vitamins, choline, lecithin, inositol, PABA, biotin, or bioflavomoids; (3) a carotenoid such as lycopene or lutein; (4) a hormone such as dehydroepiandrosterone, progesterone, pregnenolone, or melatonin; (5)... |
| Amino acid compositions | 20070286909 | 20071213 |
| Compositions are described herein that are nutritional supplements that contain free amino acids. These supplements contain a homogenous mixture of free amino acids, wherein the free-form amino acids comprise L-Lysine, L-Valine, L-Tryptophan, L-Phenylalanine, L-methionine, L-Leucine, L-Threonine, L-Isoleucine, L-Arginine, L-Histidine, L-Tyrosine, L-Carnitine, L-Serine, L-Glutamine, Aspartic Acid, L-Proline, L-Glycine, Taurine, L-Cysteine, Gamma-aminobutyric acid (GABA), L-Alanine, L-Glutamic acid, and wherein the composition comprises at least one B vitamin. These compositions are of use to treat disorders associated with a deficiency at least one amino acid, such as soft tissue injury, insomnia, panic attacks, anxiety disorders, eating disorders, anorexia, depression, chronic pain, emotional distress, chemical dependence, alcoholism, and hypoglycemia.
... |
| Glutamine-containing energy imparting amino acid composition or amino acid solution | 20070276029 | 20071129 |
| [Problems] Amino acid composition with substantially no side effects which can not only efficiently supplement energy but also elevate the motor function. [Means for Solving Problems] Energy-imparting amino acid composition or amino acid solution containing glutamine comprising proline, alanine, valine, isoleucine, lysine and the glutamine. The energy-imparting amino acid composition is superior to the conventional amino acid compositions containing no glutamine in the energy supplementation and the motor function.
... |
| Sport drink containing amino acids and carbohydrates | 20070270355 | 20071122 |
| A composition includes a plurality of amino acids. The plurality of amino acids includes at least one essential amino acid and at least one non-essential amino acid. The plurality of amino acids also includes at least one branch-chain amino acid. The composition also includes a source of carbohydrates. The compositions also includes purified water. The plurality of amino acids comprises about 1 wt % of the composition. A composition includes a plurality of amino acids, sodium citrate, sodium chloride, potassium phosphate, flavoring, a source of carbohydrates, and purified water. In some embodiments of the composition, the plurality of amino acids includes alanine, arginine, aspartate, cystine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonin, tryptophan, tyrosine, and valine.
... |
| 8-hydroxyquinoline compounds for treating a polyglutamine (polyq)-expansion disease | 20070270462 | 20071122 |
| The present invention provides compositions and methods of treating a polyglutamine (poly Q) expansion disease in a subject using an 8-hydroxyquinoline compound.
... |
| Tuberculosis vaccines including recombinant bcg strains expressing alanine dehydrogenase, serine dehydratase and/or glutamine synthetase | 20070264286 | 20071115 |
| The invention relates to a live recombinant Mycobacterium bovis-BCG strain comprising a nucleic acid capable of expression, the nucleic acid encoding at least one protein or polypeptide that exhibits alanine dehydrogenase activity, glutamine synthetase activity, or serine dehydratase activity.
... |
| Encapsulated oil-in-water type emulsion composition | 20070265347 | 20071115 |
| Encapsulated oil-in-water type emulsion compositions, which comprise an acylamino acid alkylamide or an acylglutamine alkyl ester, an oily base, a polar solvent and water, do no exhibit coalescence of the dispersed phase, and can be produced by a simple method without resort to a special apparatus, are excellent in stability with time, do not impart an uncomfortable feeling during application, are excellent in a sensory feeling that satisfies both a moisturizing feeling and an emollient feeling, and are excellent in appearance.
... |
| Methods and reagents for activating heat shock protein 70 | 20070259820 | 20071108 |
| The present disclosure is directed to new compounds useful as modulators of Heat Shock Proteins (HSP). In particular, the present disclosure provides new small molecule peptide-derived compounds having HSP modulation activity, especially Hsp70 modulation activity, and methods of preventing or ameliorating beta-amyloid or polyglutamine aggregation, decreasing cell proliferation, or increasing chaperon activity of the HSPs.
... |
| L-amino acid-producing bacterium and a method for producing l-amino acid | 20070254345 | 20071101 |
| Coryneform bacteria are described that have an ability to produce L-amino acids and are modified so that acetyl-CoA hydrolase activity is decreased. The bacteria are used to produce L-amino acids generated by a biosynthetic pathway in which pyruvic acid is an intermediate, such as L-glutamic acid, L-arginine, L-glutamine, L-proline, L-alanine, L-valine, and L-lysine.
... |
| Suppressing polyglutamine aggregation and toxicity | 20070244057 | 20071018 |
| It has been discovered that CHIP suppresses polyglutamine aggregation and toxicity in transfected cell lines, primary neurons and a novel zebrafish model of disease. Accordingly, certain embodiments of the present invention provide methods for decreasing the formation of an inclusion or aggregation of a protein or for increasing the solubility of a protein in a cell, comprising increasing the amount of C-terminal heat shock protein 70-interacting protein (CHIP) or a functional subunit of CHIP in the cell. Additionally, certain embodiments of the present invention provide methods for treating a subject that has a neurodegenerative disease or preventing a neurodegenerative disease in a subject, comprising administering to the subject a treatment effective to increase the amount of CHIP, or a functional subunit thereof, in cells of the... |
| Method of making theanine | 20070224667 | 20070927 |
| In a method of making theanine, glutaminase is derived from microbes of one or more of Bacillus, mold and yeast is caused to act on glutamine and ethylamine derivative.
... |
| Alcohol metabolism moderating composition | 20070218106 | 20070920 |
| The present invention is directed to a composition, in particular a food composition, or dietary supplementation which is active in respect to the support and/or the moderation of an alcohol degradation process within the human body. The present invention particularly addresses the problem of rapid alcohol degradation i.e. alcohol metabolism as may occur in most people of Non-Caucasian type genetic structure. In this regard, an object of the present invention is to achieve solutions which provide a reduction in the physiological stress in connection with the consumption of alcohol in particular for people with a predisposition towards rapid alcohol degradation. According to the present invention this object is attained by a food composition or dietary supplementation including the following substances: dextrose, Vitamin C, L-glutamine cysteine, riboflavin,... |
| Food ingredient including enriched free amino acids and their production method | 20070212447 | 20070913 |
| The present invention provides a food ingredient including elevated content of free amino acids such as glutamine, valine, isoleucine, leucine and arginine in whole meal of a seed of wheat or barley, ground products of a seed of wheat or barley during maturation period from immediately after the heading until the maturation, and the like, and its production method. More particularly, a food ingredient that is whole meal of a seed of wheat or barley, wherein the content of free glutamine is 200 to 1200 mg/100 g, the content of valine is 40 to 150 mg/100 g, the content of isoleucine is 30 to 120 mg/100g, the content of leucine is 40 to 150 mg/100 g and the content of arginine is 60 to 150 mg/100... |
| Methods and apparatus for preserving the endothelium in isolated hollow organs and biological vessels | 20070202485 | 20070830 |
| The invention relates to a method and an apparatus for the endothelium-preserving treatment of isolated hollow organs, especially biological vessels such as blood vessels and lymphatic vessels by means of endothelium-protective perfusates or incubation solutions containing at least 0.1 percent by weight of native albumin and a nutrient substrate, preferably L-glutamine. Also disclosed are the use of the endothelium-protective perfusates for preparing hollow organs or biological vessels as a transplant for the treatment of organ diseases or vascular diseases, the use thereof for repairing endothelial lesions in isolated hollow organs and/or biological vessels, and the use thereof for preserving organs and/or vessels.
... |
| Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise | 20070196508 | 20070823 |
| The present invention relates to a dietary supplement that comprises at least Creatine or derivatives thereof, Taurine or derivatives thereof and a source of Phosphate. The dietary supplement may further comprise one or more of the following: Double Fermented Triticum aestivum, Dextrose, Isomalt, Trehalose, D-Mannose, Mulberry extract, Enicostemma littorale Blume, Scoparia dulcis, Tarragon extract, Andrographis paniculata, Chromium or derivatives thereof, Glutamine and Alpha Lipoic Acid. The present invention may also provide a method for increasing Creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and aiding in recovery following exercise as well as supporting the immune system during periods of intense training.
... |
| Method of site specific labeling of proteins and uses therefor | 20070190578 | 20070816 |
| Methods for site-specific modification of protein are provided. These methods modify proteins which have been labeled at a particular site by the reaction of a transglutaminase with a glutamine peptide sequence which has been engineered into the protein. The site-specific modification methods of the invention are useful for producing reagents useful in high throughput screening methods and in producing protein delivery vehicles for specifically targeting cellular and non-cellular targets. Also described are improved biotinylation reagents.
... |
| Nucleic acid encoding an interleukin-9 receptor variant | 20070190609 | 20070816 |
| This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and... |
| Alpha-amylase variants having an elevated solvent stability, method for the production thereof and detergents and cleansers containing these alpha-amylase variants | 20070190632 | 20070816 |
| The present invention relates to α-amylase variants that are stabilized to solvent-exerted hydrolysis, in particular at elevated temperatures or high pH, by point mutagenesis of asparagine (N) or glutamine (Q) residues located on the surface of the molecule to give other amino acid residues. The invention further relates to methods of increasing the stability of an α-amylase to solvent-exerted hydrolysis, in particular at elevated temperatures or high pH, whereby at least one asparagine (N) or glutamine (Q) residue on the surface of the molecule is replaced with a different amino acid residue. The α-amylase variants obtained thereby exhibit better stability to influences of the solvent, increased processivity, and are suited for numerous industrial areas of use, in particular as active ingredients in detergents and cleansers.
... |
| Method for the linkage of bifunctional chelating agents and (radioactive) transition metal complexes to proteins and peptides | 20070184537 | 20070809 |
| The present invention relates to a method for radioactive labeling of a protein or peptide, by providing a protein or peptide having at least one glutamine or lysine residue; adding a metal chelating agent having at least one lysine or glutamine residue, respectively, which metal chelating agent is optionally complexed with a radioactive or paramagnetic metal; reacting the protein or peptide and metal chelating agent in the presence of a transglutaminase to obtain a protein or peptide with a metal chelating group covalently bound thereto, and optionally complexing the metal chelating group with a radioactive or paramagnetic metal. The invention also relates to proteins and peptides thus labeled and to proteins and peptides that have been coupled to a metal chelating agent but not yet labeled.
... |
| Glycopeptides for the treatment of als and other metabolic and autoimmune disorders | 20070185012 | 20070809 |
| New compositions and methods for treating patients suffering from Amyotrophic Lateral Sclerosis (ALS) and other metabolic and autoimmune disorders, which include glycopeptides such as N-acetyl-D-glucosaminyl(β1-4)-N-Acetyl-muramyl-L-alanyl-D-isoglutamine (GMDP) and peptide analog-L-alanyl-D-glutamic acid (GMDP-A) of at least 98% purity administered either alone, or in combination with a flavone such as luteolin and/or an isoflavone such as genistein, optionally in combination with a flavonol glycoside such as isoquercitrin or rutin. The high purity glycopeptides have a decreased amount immunogenic impurities and demonstrate a synergistic effect when combined with luteolin and/or genistein in presence of isoquercitrin.
... |
| Reducing polyglutamine-based aggregation | 20070185031 | 20070809 |
| The disclosure features, inter alia, methods for treating or preventing neurodegenerative disorders and disorders that caused at least in part by polyglutamine aggregation. The method can include reducing activity of the IGF-1/GH axis in a subject. One exemplary neurodegenerative disorder that is also caused at least in part by polyglutamine aggregation is Huntington's disease.
... |
| Prediction method for lipidosis | 20070166829 | 20070719 |
| The present invention provides a prediction method for lipidosis caused by a compound, which comprises detecting (a) phenylacetylglycine and/or phenylacetylglutamine, or an optionally chosen metabolic intermediate in the metabolic pathway from phenylalanine to phenylacetylglycine or phenylacetylglutamine, and (b) hippuric acid or an optionally chosen metabolic intermediate in the metabolic pathway from phenylalanine to hippuric acid, in a sample collected from a mammal receiving the compound or a mammalian cell or tissue culture exposed to the compound, and predicting the compound's potential for inducing lipidosis with the quantitative ratio of the two as the index. The present invention also provides a diagnostic method for lipidosis and diseases related thereto, comprising detecting (a) and (b) above in a sample collected from a mammal, and making a diagnosis with... |
| Diagnostic agents for pancreatic exocrine function | 20070154394 | 20070705 |
| Y1 is a 13C-labeled alanine molecule optionally having a protecting group.
... |
| Hypoglycemic agent | 20070155655 | 20070705 |
| A zinc(II) complex which is lowly toxic, has high insulin-like activity, and is effectively usable as a hypoglycemic agent for the prevention or treatment of diabetes; a hypoglycemic agent containing the complex; a medicinal preparation which contains the complex and is useful as a preventive/remedy for diabetes; and a food containing the complex, such as a health food or supplementary health food. The hypoglycemic agent contains an organic zinc(II) complex having as a ligand a compound selected among aminoalkylpyridines, bis-optically active amino acids, bisaminoalkylcarboxylic acids, oligopeptides, oligopseudopeptides, di-substituted aminocarboxylic acids, α- and β-hydroxycarboxylic acids, vitamins, glutamine derivatives, etc.
... |
| Hypoglycemic agent | 20070155656 | 20070705 |
| A zinc(II) complex which is lowly toxic, has high insulin-like activity, and is effectively usable as a hypoglycemic agent for the prevention or treatment of diabetes; a hypoglycemic agent containing the complex; a medicinal preparation which contains the complex and is useful as a preventive/remedy for diabetes; and a food containing the complex, such as a health food or supplementary health food. The hypoglycemic agent contains an organic zinc(II) complex having as a ligand a compound selected among aminoalkylpyridines, bis-optically active amino acids, bisaminoalkylcarboxylic acids, oligopeptides, oligopseudopeptides, di-substituted aminocarboxylic acids, α- and β-hydroxycarboxylic acids, vitamins, glutamine derivatives, etc.
... |
| Hypoglycemic agent | 20070155657 | 20070705 |
| A zinc(II) complex which is lowly toxic, has high insulin-like activity, and is effectively usable as a hypoglycemic agent for the prevention or treatment of diabetes; a hypoglycemic agent containing the complex; a medicinal preparation which contains the complex and is useful as a preventive/remedy for diabetes; and a food containing the complex, such as a health food or supplementary health food. The hypoglycemic agent contains an organic zinc(II) complex having as a ligand a compound selected among aminoalkylpyridines, bis-optically active amino acids, bisaminoalkylcarboxylic acids, oligopeptides, oligopseudopeptides, di-substituted aminocarboxylic acids, α- and β-hydroxycarboxylic acids, vitamins, glutamine derivatives, etc.
... |
| Medium and method for measuring the efficacy of a tumour therapy | 20070142724 | 20070621 |
| According to the invention, a measurement of the efficacy of a tumour therapy in single cell suspensions of tumour cells, by determination of the acid formation in a medium in the presence and the absence of a cytotoxic substance, is carried out by performing the measurement in a medium comprising 0.1 to 1 mM of a pH 7.0 to 7.4 buffer, 2 to 10 g/l glucose, 2 to 5 mM glutamine as the carbon source and 5 to 20 vol. % fetal calf serum.
... |
| Inhibitors of histone deacetylase for the treatment of disease | 20070135431 | 20070614 |
| or a salt, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
... |
| Inhibitors of histone deacetylase for the treatment of disease | 20070135438 | 20070614 |
| or a pharmaceutically acceptable salt, ester, or prodrug thereof, Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.
... |
| Labelled glutamine and lysine analogues | 20060292075 | 20061228 |
| Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.
... |
| Glutamine-rich maize seed protein and promoter | 20060288443 | 20061221 |
| Provided is a nucleotide sequence encoding a 55 kDa maize prolamin family protein. Also provided is a nucleotide sequence derived from the promoter of the 55 kDa maize gene that can be used to express heterologous sequences in plants, and methods of using the disclosed nucleotide sequences.
... |
| Compositions and methods of treating and diagnosing hepatoma | 20060280725 | 20061214 |
| Disclosed are pharmaceutical compositions and methods of treating hepatoma by administering to patients or other populations of cells agents that selectively inhibit the uptake of glutamine by hepatocarcinoma cells, causing the concomitant apoptosis of hepatocarcinoma cells. Preferred agents target the amino acid transporter B0 (ATB0) protein for inhibition. Disclosed are antisense polynucleotides that reduce the expression of ATB0 in hepatocarcinoma cells, causing those cells to reduce the uptake of glutamine and subsequently undergo selective apoptosis.
... |
| Cyclin groove inhibitors | 20060281687 | 20061214 |
| A is (i) a natural or unnatural amino acid residue having a side chain comprising at least one H-bond acceptor moiety and at least one H-bond donor moiety, or a derivative thereof; or (ii) R(CO), wherein R is a C1-C24 hydrocarbyl group comprising at least one H-bond acceptor moiety and optionally one or more H-bond donor moieties, and where R optionally contains one or more heteroatoms selected from S, O, and N, and is optionally substituted by one or more substituents selected from halogen, OMe, CN, CF3, and NO2; each of B and D is independently an amino acid residue selected from arginine, 4-(guanidinyl)phenylalanine (4-(Gu)Phe), piperidinylglycine (PipGly), piperidinylalanine (PipAla), pyridinylalanine, histamine, N,N-(dimethyl) lysine (DMLys), citrulline, glutamine, serine, lysine, asparagine, isoleucine and alanine, or a derivative thereof;... |
| Method of preparing a heat-treated product | 20060275879 | 20061207 |
| The formation of acrylamide during heat treatment in the production of a food product is reduced by treating the raw material with an enzyme before the heat treatment. The enzyme is capable of reacting on asparagine or glutamine (optionally substituted) as a substrate or is a laccase or a peroxidase.
... |
| Prevention and treatment of influenza with glutamine antagonist agents | 20060276438 | 20061207 |
| A method of preventing or treating influenza or an influenza-related symptom in a subject by administering to the subject a glutamine antagonist agent is described.
... |
| New strains of bifidobacterium having the ability to produce glutamine | 20060269533 | 20061130 |
| The invention refers to new strains of Bifidobacterium, especially of the species Bifidobacterium infantis, having the ability to survive in the intestinal tract and to produce glutamine and optionally arginine in vivo, as well as to compositions comprising said strains.
... |
| Rna interference mediated treatment of polyglutamine (polyq) repeat expansion diseases using short interfering nucleic acid (sina) | 20060270623 | 20061130 |
| The present invention concerns compounds, compositions, and methods for the study, diagnosis, and treatment of diseases and conditions associated with polyglutamine repeat (polyQ) allelic variants that respond to the modulation of gene expression and/or activity. The present invention also concerns compounds, compositions, and methods relating to diseases and conditions associated with polyglutamine repeat (polyQ) allelic variants that respond to the modulation of expression and/or activity of genes involved in polyQ repeat gene expression pathways or other cellular processes that mediate the maintenance or development of polyQ repeat diseases and conditions such as Huntington disease and related conditions such as progressive chorea, rigidity, dementia, and seizures, spinocerebellar ataxia, spinal and bulbar muscular dystrophy (SBMA), dentatorubropallidoluysian atrophy (DRPLA), and any other diseases or conditions that are related to... |
| Postsynaptic proteins | 20060252677 | 20061109 |
| A protein A that binds to the N-methyl-D-aspartate (NMDA) receptor and a protein B that interacts with protein A are provided. Furthermore, based on the marked promotion of the NMDA receptor mediated signal transduction by these proteins, providing a controlling agent (an inhibiting agent or a promoting agent) and a controlling method for the expression and/or the function of these proteins makes possible the elucidation of diseases caused by an anomaly in the NMDA receptor mediated signal transduction or in memory recall, including such neurodegenerative diseases as Alzheimer's disease, Parkinson's disease and polyglutamine disease, and allows for the prevention, improvement or treatment thereof.
... |
| Methods for reducing levels of disease associated proteins | 20060252775 | 20061109 |
| The subject invention concerns the reduction of protein aggregation in the neurons of a mammal through the use of a ketogenic treatment such as a ketogenic diet, a physical training regimen and/or administration of agents to increase fatty acid oxidation. Such ketogenic treatment can be useful in the reduction of certain aggregates including amyloid β peptide, polyglutamine containing huntintin protein, polyglutamine containing androgen receptor, polyglutamine containing atrophin-1, polyglutamine containing ataxins, α-synclein, prion protein, tau and superoxide dismutase 1 (SOD1).
... |
| Toothpaste containing anticancer agents | 20060246016 | 20061102 |
| A novel dentifrice composition is provided for prevention or treatment of carcinoma of the oral cavity, caries and periodontal diseases of the oral cavity. The dentifrice composition contains a silica abrasive and medicinal agents useful in the treatment of human neoplastic disease. The medicinal agent is selected from the group consisting of 3-N-phenylacetylamino-2,6-piperidinedione, phenylacetylglutamine, phenylacetylisoglutamine, phenylbutyrate, phenylacetate, combinations thereof and pharmaceutically acceptable salts thereof. The components of the dentifrice composition act advantageously to allow the composition to remove plaque, tartar, and oral disease-causing bacteria.
... |
| Amino acid composition promoting collagen synthesis | 20060247313 | 20061102 |
| Herein are disclosed an excellent collagen synthesis-promoting amino acid composition that are characterized by containing specific amino acids at a specific ratio, more specifically, by containing 10-40 parts by weight of L-arginine and/or 10-40 parts by weight of L-glutamine, as well as 5-20 parts by weight of L-valine, 8-30 parts by weight of L-isoleucine and 10-35 parts by weight of L-leucine, an amino acid composition that inhibits skin aging, an amino acid composition that suppresses osteoporosis, an amino acid composition that promotes regeneration of tendon and ligament, and an amino acid composition that heals wounds or thermal burns, that are of the same composition.
... |
| Glutamine:fructose-6-phosphate amidotransferase(gfat) comprising an internal purification marker and use thereof for the screening of compounds | 20060239989 | 20061026 |
| The invention relates to a protein with enzymatic activity, comprising a GFAT sequence and at least one sequence of a purification marker, the sequence for the purification marker being inserted between two consecutive amino acids of the GFAT sequence.
... |
| Cartilaginous cell culture medium and the use thereof | 20060233763 | 20061019 |
| A cartilage cell culture medium comprising a basic medium suitable for culturing primary human cells and, said culture medium additionally containing 0.5 to 50.0 ng/ml of EGF, 0.5 to 50.0 ng/ml of FGF, 0.1 to 10.0 ng/ml of PDGF, 0.5 to 50.0 ng/ml of IGF, 1.0 to 100.0 ng/ml of dexamethasone, and 0.1 to 10.0 mM of glutamine, optionally supplemented with 0 to 15% of autologous human serum. In a second aspect, the invention relates to the use of a cartilage cell culture medium as defined above for culturing cartilage cells (chondrocytes).
... |
| Polyglutamine repeat sequences | 20060234385 | 20061019 |
| Several neurodegenerative diseases result from the aggregation of polyglutamine repeat proteins into insoluble neuronal intranuclear inclusions. The invention provides methods with which to study the processes of these diseases, including methods for solubilizing polypeptides containing a polyglutamine repeat sequence, for storing these polyglutamine polypeptides and inhibit their spontaneous aggregation, for making the aggregates of polyglutamine polypeptides, for assaying the extension of existing polyglutamine aggregates, for determining the ability of a chemical compound to inhibit aggregation, and for inhibiting aggregation of polyglutamine polypeptides. The invention further provides materials with which to study these diseases including a synthetic aggregate that have a capability to recruit additional monomeric polyglutamine polypeptides and chemical compounds that inhibit the formation and/or extension of polyglutamine aggregates.
... |
| Enternal administration of arginine and glutamine for abnormal vascular proliferation | 20060229256 | 20061012 |
| The subject invention provides a method and compositions for preventing and/or treating abnormal vascular proliferation in a human infant where the method involves enterally administering arginine and glutamine to the infant in about equimolar amounts to provide a total amount of arginine and glutamine that is effective to prevent or treat the abnormal vascular proliferation. Arginyl-glutamine dipeptide was shown to be an advantageous form in which to provide the two amino acids.
... |
| Method for synthesizing amino-acid-selectively labeled protein | 20060216791 | 20060928 |
| An object of the present invention is to provide a method for synthesizing, in a cell-free protein synthetic system using a wheat germ extract, a protein of interest that is labeled in an amino-acid-selective manner. The present invention provides a method for carrying out a translation reaction of a protein of interest under a condition whereby a metabolic reaction of alanine to aspartic acid and glutamic acid, a metabolic reaction of aspartic acid to glutamic acid or a metabolic reaction of glutamic acid to aspartic acid and/or glutamine is inhibited, while the protein synthesis is not inhibited, when alanine, aspartic acid or glutamic acid of the protein of interest is labeled with a stable isotope in a cell-free protein synthetic system containing a wheat germ extract.
... |
| Sequence-determined dna fragments encoding glutamine amidotransferase proteins | 20060217541 | 20060928 |
| The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3′ termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.
... |
| Sequence-determined dna fragments encoding glutamine amidotransferase proteins | 20060211851 | 20060921 |
| The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3′ termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait.
... |
| Biologic variability of asthma associated factors useful in treating and diagnosing atopic allergies including asthma and related disorders | 20060205035 | 20060914 |
| This invention relates to the diagnosis, treatment and methods for discovery of new therapeutics for atopic asthma and related disorders based on variants of Asthma Associated Factor 2. One embodiment of the invention is a variant of AAF2 wherein codon 173 is deleted resulting in the loss of glutamine 173 from the mature protein precursor. This single amino acid deletion results in a non-functional AAF2 protein and therefore the presence of this phenotype should be associated with less evidence of atopic asthma. Correspondingly, the lack of susceptibility to an asthmatic, atopic phenotype is characterized by the loss of glutamine at codon 171 The invention includes isolated DNA molecules which are variants of the wild type sequence as well as the proteins encoded by such DNA and... |
| Method for the treatment of von hippel-lindau (vhl) disease with phenylacetyl-derivatives | 20060205818 | 20060914 |
| Provided are methods of treating von Hippel-Lindau disease (VHL). Specifically embodiments of the invention provide methods for the treatment of a patient afflicted with VHL using phenylacetyl-derivatives. Preferred embodiments of the invention provide for the use of phenylacetic acid (or its sodium salt), phenylacetylglutamine (or its sodium salt) and/or phenylacetylisoglutamine (or its sodium salt) to treat VHL. Other embodiments of the invention provide for the use of phenylacetyl-derivatives for the manufacture of a medicament for the treatment of VHL.
... |
| Supplemental dietary composition for supporting muscle growth, recovery and strength | 20060198899 | 20060907 |
| Methods and compositions for the purposes muscle growth, recovery and/or strength are set forth. The compositions may include, but are not limited to, creatine monohydrate, glutamine alpha-ketoglutarate, glutamine, glutamine peptides, L-glutamine, L-leucine, L-valine, L-isoleucine and guar gum. The supplemental dietary compositions may be suitable for persons seeking to improve strength and recovery for exercise while supporting muscle growth.
... |
| Q3 sparc deletion mutant and uses thereof | 20060199248 | 20060907 |
| The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature form of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies.
... |
| Method for producing amino acids by fermentation | 20060194302 | 20060831 |
| The present invention provides a method for producing an amino acid selected from the group consisting of L-alanine, L-valine, L-leucine, L-isoleucine, L-methionine, L-phenylalanine, L-proline, glycine, L-serine, L-threonine, L-cysteine, L-tyrosine, L-asparagine, L-glutamine, L-lysine, L-histidine, L-arginine, L-aspartic acid and L-glutamic acid and useful as medicament, chemical agent, food material and feed additive at high industrial efficiency, the method comprising culturing a microorganism having an ability to produce the amino acid and having resistance to an aminoquinoline derivative in a medium, producing and accumulating the amino acid in the present invention in the culture, and recovering the amino acid from the culture.
... |
| Culture media compositions free of fetal bovine serum | 20060194322 | 20060831 |
| A cell culture growth media free of Fetal Bovine Serum for use with parasitic organisms. The media includes calcium chloride, sodium bicarbonate, potassium chloride, sodium chloride, monosodium phosphate, glucose, hepes, ferric nitrate, magnesium sulfate, tricine, d-ribose, 2-deoxy ribose, adenosine-5-triphosphate (ATP), 2-deoxyadenylic acid (d-AMP), 5′-thymidylic acid (TMP), 2′-deoxyicitidine-5 monophosphate (d, 2′-deoxyuridine-5-monophosphate (d, 2′-deoxyguanilic Acid (d-GMP), aspartic acid, glutamic acid, 1-alanine, arginine, camosine, cysteine, cystine, glutamine, glycine, histidine, iso-leucine, leucine, lysine, methionine, omitine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, ascorbic acid, biotine (H), camitine, cholecalciferol, choline chloride, cyanocobalamine (B12), ergocalciferol, folic acid, myo-inositol, menadione, nicotinamide, PABA, panthotenato, pyridoxal, pyridoxamine, pyridoxine, retinol (A), riboflavine (B2), Thiamine (B1), 6,8 Thiotic acid, alfa-tocoferol, 3-phytylnenadione (K1), tetrahydrofolic acid, hemin from procine, and nanopure water.
... |
| Mutant protein | 20060194950 | 20060831 |
| The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.
... |
| Protein ligands | 20060194955 | 20060831 |
| The present invention relates to the use of an alkali-stable protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other... |
| Treatment of mycobacterium tuberculosis with antisense oligonucleotides | 20060183676 | 20060817 |
| Methods of inhibiting the proliferation of Mycobacterium tuberculosis comprising contacting Mycobacterium tuberculosis with an effective amount of a polynucleotide complementary to an mRNA transcript expressed by Mycobacterium tuberculosis are provided. Typical methods of the invention utilize phosphorothioate modified antisense polynucleotides (PS-ODNs) against the mRNA of M. tuberculosis genes such as glutamine synthetase, aroA, ask, groES, and the genes of the Antigen 85 complex. Optionally, the methods employ multiple antisense polynucleotides targeting different Mycobacterium tuberculosis transcripts. In preferred embodiments of the invention, the antisense polynucleotides are complementary to the 5′ regions of the Mycobacterium tuberculosis transcripts.
... |
| Compositions of orthogonal lysyl-trna and aminoacyl-trna synthetase pairs and uses thereof | 20060177900 | 20060810 |
| Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases, and orthogonal pairs of lysyl-tRNAs/synthetases, which incorporate homoglutamines into proteins are provided in response to a four base codon. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with homoglutamines using these orthogonal pairs.
... |
| Production of alpha-abeta | 20060160180 | 20060720 |
| An improved system for large scale production of proteins and/or polypeptides in cell culture, particularly in media characterized by one or more of: i) a cumulative amino acid concentration greater than about 70 mM; ii) a molar cumulative glutamine to cumulative asparagine ratio of less than about 2; iii) a molar cumulative glutamine to cumulative total amino acid ratio of less than about 0.2; iv) a molar cumulative inorganic ion to cumulative total amino acid ratio between about 0.4 to 1; or v) a combined cumulative glutamine and cumulative asparagine concentration between about 16 and 36 mM, is provided. The use of such a system allows high levels of protein production and lessens accumulation of certain undesirable factors such as ammonium and/or lactate. Additionally, culture methods... |
